Eli Lilly and Company (LLY)vsNeogen Corporation (NEOG)
LLY
Eli Lilly and Company
$1,372.99
+6.63%
HEALTHCARE · Cap: $1.12T
NEOG
Neogen Corporation
$12.26
+1.16%
HEALTHCARE · Cap: $2.58B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 8912% more annual revenue ($79.67B vs $884.00M). LLY leads profitability with a 33.5% profit margin vs -6.3%. NEOG appears more attractively valued with a PEG of 0.66. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
NEOG
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+80.7%
Fair Value
$55.64
Current Price
$12.26
$43.38 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Reasonable price relative to book value
Growing faster than its price suggests
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 36.1x book value
ROE of -29.0% — below average capital efficiency
Earnings declined 85.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : NEOG
The strongest argument for NEOG centers on Price/Book, PEG Ratio. PEG of 0.66 suggests the stock is reasonably priced for its growth.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 42.2x leaves little room for execution misses. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : NEOG
The primary concerns for NEOG are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
LLY profiles as a growth stock while NEOG is a turnaround play — different risk/reward profiles.
NEOG carries more volatility with a beta of 1.79 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 44/100), backed by strong 33.5% margins and 47.7% revenue growth. NEOG offers better value entry with a 80.7% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Neogen Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Neogen Corporation, develops, manufactures and markets various products for food and animal safety worldwide. The company is headquartered in Lansing, Michigan.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?